Efficacy and safety of transarterial chemoembolization + vitamin K combination treatment against hepatocellular carcinoma-Open label, randomized, phase 2 study

Efficacy and safety of transarterial chemoembolization + vitamin K combination treatment against hepatocellular carcinoma-Open label, randomized, phase 2 study - TACE + vitamin K treatment

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026404

Enrollment

200

Registered

2017-03-09

Start date

2017-03-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

daily dosing of vitamin K2(45mg) since one day before the transarterial chemoembolization to 28 days after transarterial chemoembolization without vitamin K dosing

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients indicated to transarterial chemoembolization against hepatocellular carcinoma, ECOG PS 0 or 1, Child-Pugh score 5-7, obtained written informed consent

Exclusion criteria

Exclusion criteria: Patients who underwent previous transarterial chemoenmbolization greater than twice, patients with warfarin dosing, patients who have been given vitamin K before the enrollment

Design outcomes

Primary

Measure	Time frame
Treatment effect 4 weeks after transarterial chemoembolization	—

Secondary

Measure	Time frame
Progression free survival	—

Countries

Japan

Contacts

Public ContactYoshimichi Haruna

Osaka General Medical Center Department of Laboratory Medicine

apple-123-grape@ab.auone-net.jp+81666921201

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026